Evaluation of PTK7 expression in hematologic malignancies
| Disease . | n . | PTK7+, no. (%) . |
|---|---|---|
| AML | 257 | 184 (72) |
| ALL | 39 | 11 (27) |
| BAL | 5 | 5 (100) |
| NHL | 7 | 0 |
| CLL | 6 | 0 |
| MPS | 3 | 2 (67) |
| CMML | 3 | 0 |
| CML | 3 (1 CP, 2 BP) | 2 (67) |
| Disease . | n . | PTK7+, no. (%) . |
|---|---|---|
| AML | 257 | 184 (72) |
| ALL | 39 | 11 (27) |
| BAL | 5 | 5 (100) |
| NHL | 7 | 0 |
| CLL | 6 | 0 |
| MPS | 3 | 2 (67) |
| CMML | 3 | 0 |
| CML | 3 (1 CP, 2 BP) | 2 (67) |
Expression of PTK7 was evaluated by flow cytometry in AML.
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; BAL, biphenotypic acute leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MPS, myeloproliferative syndrome; CMML, chronic myelomonocytic leukemia; CML, chronic myeloid leukemia; CP, chronic phase; BP, myeloid blastic phase.